Edition:
United States

Voyager Therapeutics Inc (VYGR.OQ)

VYGR.OQ on NASDAQ Stock Exchange Global Select Market

19.36USD
16 Feb 2018
Change (% chg)

$0.19 (+0.99%)
Prev Close
$19.17
Open
$19.15
Day's High
$19.69
Day's Low
$19.11
Volume
52,814
Avg. Vol
166,357
52-wk High
$25.93
52-wk Low
$8.10

Select another date:

Tue, Jan 23 2018

BRIEF-Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC

* VOYAGER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR VY-AADC FOR ADVANCED PARKINSON’S DISEASE

BRIEF-Ophthotech Announces Election Of Jane Pritchett Henderson, CFO And Senior Vice President Of Corporate Development At Voyager Therapeutics, To Its Board Of Directors

* OPHTHOTECH ANNOUNCES ELECTION OF JANE PRITCHETT HENDERSON, CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT AT VOYAGER THERAPEUTICS, TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-BB Biotech Reports 5.6% Passive Stake In Voyager Therapeutics

* BB BIOTECH AG REPORTS 5.6% PASSIVE STAKE IN VOYAGER THERAPEUTICS AS OF JAN 3 - SEC FILING‍​ Source text: (http://bit.ly/2CZEeZD) Further company coverage:

BRIEF-Voyager Therapeutics prices public offering of 4.50 mln common shares at $12/shr

* Voyager Therapeutics announces pricing of public offering of common stock

BRIEF-Voyager Therapeutics announces proposed offering of common stock

* Voyager Therapeutics announces proposed offering of common stock

BRIEF-Voyager Therapeutics reports Q3 GAAP loss per share $0.89

* Voyager Therapeutics Inc reports third quarter 2017 financial results and corporate highlights

BRIEF-Voyager Therapeutics reports positive results from ongoing trial for advanced parkinson’s disease

* Voyager Therapeutics announces positive results from ongoing Phase 1b trial of VY-AADC01 for advanced parkinson’s disease

Select another date: